Journal
European urology
Publication Date
12-1-2018
Volume
74
Issue
6
First Page
731
Last Page
738
Document Type
Open Access Publication
DOI
10.1016/j.eururo.2018.08.019
Rights and Permissions
McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. Eur Urol. 2018 Dec;74(6):731-738. doi: 10.1016/j.eururo.2018.08.019 © 2018 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access articleunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Recommended Citation
McKiernan, James; Donovan, Michael J; Margolis, Eric; Partin, Alan; Carter, Ballentine; Brown, Gordon; Torkler, Phillipp; Noerholm, Mikkel; Skog, Johan; Shore, Neal; Andriole, Gerry; Thompson, Ian; and Carroll, Peter, "A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10ng/ml at initial biopsy." European urology. 74, 6. 731 - 738. (2018).
https://digitalcommons.wustl.edu/open_access_pubs/8219
Supplementary Tables
1-s2.0-S0302283818306043-mmc2.pdf (313 kB)
‘CarePath’ for Clinical implementation of the EPI test in Cohort 2 of the Registration and Utility Trial.
